Table 3.
Cox proportional (unadjusted and adjusted) hazard ratios and 95% confidence intervals for morbidity, loss to follow-up, and mortality.
| Morbidity | Loss to follow-up | Mortality | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Unadjusted | Adjustedb | Unadjusted | Adjustedb | Unadjusted | Adjustedb | |||||||
|
| ||||||||||||
| Covariate | HR (95% CI) |
P value | HR (95% CI) |
P value | HR (95% CI) |
P value | HR (95% CI) |
P value | HR (95% CI) |
P value | HR (95% CI) |
P value |
| Enrolled during cap period | 0.93 (0.83, 1.03) |
0.162 | 0.92 (0.82, 1.03) |
0.152 | 1.19 (1.11, 1.27) |
<0.001 | 1.12 (1.04, 1.22) |
0.004 | 1.31 (1.16, 1.48) |
<0.001 | 1.21 (1.06, 1.39) |
0.006 |
| Use of Cotrimoxazole or Dapsonea | 0.66 (0.58, 0.76) |
<0.001 | 0.67 (0.55, 0.80) |
<0.001 | 0.39 (0.36, 0.42) |
<0.001 | 0.58 (0.52, 0.65) |
<0.001 | 0.49 (0.42, 0.56) |
<0.001 | 0.46 (0.37, 0.57) |
<0.001 |
| TB treatmenta | 0.82 (0.72, 0.93) |
0.003 | 0.68 (0.59, 0.78) |
<0.001 | 1.04 (0.97, 1.12) |
0.299 | 0.99 (0.90, 1.09) |
0.850 | 1.11 (0.97, 1.27) | 0.136 | 0.84 (0.72, 0.99) |
0.033 |
| Male gender | 0.98 (0.88, 1.09) | 0.718 | 0.95 (0.85, 1.07) |
0.418 | 1.05 (0.98, 1.12) |
0.187 | 1.01 (0.93, 1.10) |
0.760 | 1.48 (1.31, 1.67) | <0.001 | 1.36 (1.19, 1.57) |
<0.001 |
| Age (per year increase)a | 1.00 (0.99, 1.00) |
0.333 | 1.00 (0.99, 1.01) |
0.772 | 0.99 (0.98, 0.99) | <0.001 | 0.99 (0.98, 0.99) |
<0.001 | 1.00 (1.00, 1.01) |
0.388 | 1.00 (1.00, 1.01) |
0.484 |
| CD4 (per cell increase)a | 0.999 (0.999, 1.000) |
0.006 | 0.998 (0.998, 0.999) |
<0.001 | 0.999 (0.999, 0.999) |
<0.001 | 0.999 (0.999, 0.999) |
<0.001 | 0.995 (0.994, 0.996) |
<0.001 | 0.995 (0.994, 0.996) |
<0.001 |
| WHO Stage Ia | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | ||||||
| WHO Stage IIa | 1.24 (1.01, 1.51) |
0.038 | 1.23 (1.01, 1.51) |
0.044 | 0.95 (0.83, 1.09) |
0.454 | 0.96 (0.83, 1.10) |
0.543 | 1.19 (0.87, 1.63) | 0.279 | 1.10 (0.80, 1.50) |
0.572 |
| WHO Stage IIIa | 1.49 (1.26, 1.78) |
<0.001 | 1.64 (1.36, 1.96) |
<0.001 | 1.32 (1.18, 1.49) |
<0.001 | 1.24 (1.10, 1.40) |
<0.001 | 2.62 (2.02, 3.40) |
<0.001 | 2.44 (1.87, 3.19) |
<0.001 |
| WHO Stage IVa | 2.10 (1.68, 2.62) |
<0.001 | 2.55 (2.01, 3.24) |
<0.001 | 2.08 (1.80, 2.40) |
<0.001 | 1.98 (1.70, 2.31) |
<0.001 | 4.51 (3.37, 6.04) |
<0.001 | 4.41 (3.24, 5.99) |
<0.001 |
| Urban Clinica | 0.99 (0.89, 1.10) |
0.857 | 0.99 (0.88, 1.11) |
0.856 | 1.05 (0.99, 1.12) |
0.128 | 1.02 (0.94, 1.10) |
0.651 | 0.76 (0.68, 0.87) |
<0.001 | 0.80 (0.70, 0.92) |
0.002 |
| Travel time < 30 min | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | ||||||
| Travel time 30–60 min | 0.93 (0.80, 1.07) |
0.305 | 0.95 (0.81, 1.10) |
0.491 | 1.13 (1.03, 1.24) |
0.009 | 1.14 (1.03, 1.27) |
0.014 | 1.36 (1.14, 1.62) |
<0.001 | 1.18 (0.97, 1.43) |
0.098 |
| Travel time 1-2 hr | 1.04 (0.90, 1.21) |
0.598 | 1.01 (0.86, 1.18) |
0.908 | 1.07 (0.97, 1.17) |
0.204 | 1.07 (0.96, 1.20) |
0.231 | 1.30 (1.08, 1.56) |
0.005 | 1.09 (0.89, 1.34) |
0.390 |
| Travel time > 2 hr | 0.98 (0.83, 1.17) |
0.846 | 0.93 (0.78, 1.12) |
0.464 | 1.34 (1.20, 1.48) |
<0.001 | 1.40 (1.24, 1.58) |
<0.001 | 1.38 (1.12, 1.68) |
0.002 | 1.16 (0.93, 1.45) |
0.192 |
aAt enrollment.
bAdjusted for all covariates.